Secretory Carcinoma of the Salivary Gland - Systematic Review of the Literature and Report of 2 Cases.

PURPOSE: Secretory carcinoma (SC) of the salivary gland, formerly known as mammary analogue secretory carcinoma, is an uncommon and fairly newly described low grade malignant neoplasm of the salivary gland. Given the small number of cases reported in the literature to date, treatment guidelines are scarce. This study aimed to describe the clinical characteristics of SC, discuss prior management strategies, and provide recommendations for future treatment. METHODS: We performed a systematic review of all the cases of SC reported in the literature since it was first recognized in 2010. Using Pubmed, Crossref, and Google Scholar, we identified all articles reporting cases of SC. RESULTS: We identified 657 cases of SC in 109 articles. In addition, we provided 2 new cases, for a total of 659 cases in 110 articles. To our knowledge, this is the largest review of cases of SC in the literature to date. We summarized the clinical characteristics of SC, as well as the nodal status, clinical management, recurrence rate, and death rate. CONCLUSIONS: SC occurs on average in middle age (with a large age range), presents most often initially as localized disease without metastasis, and has a low but not insignificant recurrence rate. Deaths have been reported. The generalized recommendations for treatment of SC are in line with those of other low-grade salivary gland malignancies.

Treatment of a recurrent ameloblastic fibroma.

Ameloblastic fibroma (AF), a slow-growing, benign tumor of odontogenic origin, represents 2% of all odontogenic tumors. Jaw expansion is among the most common symptoms, with diagnosis often made through routine radiographs. AFs have a recurrence rate of 18% to 43.5% after conservative enucleation. Long-term follow-up by both the surgeon and referring dentist is recommended, since recurrence may be due to regrowth of residual tumor undergoing malignant transformation. Aggressive management is recommended for local tumor recurrence. En bloc excision with bone grafting, followed by implant reconstruction, can be curative and preservative of function. Treatment of a recurrent AF is described.

Desmoplastic fibroma: report of rare lesion in unusual craniofacial location.

Desmoplastic fibroma (DF) is a benign but aggressive intraosseous tumor. These lesions are categorized as central tumors of bone. They are composed of small fibroblasts in a setting of abundant extracellular material, which is rich in collagen. DF represents fewer than 0.1% of all bony tumors. They can be found in any part of the skeleton. Based upon on our literature review, we believe this is the second reported case of desmoplastic fibroma occurring in the zygoma area.

Sebaceous carcinoma of the oral cavity: a case report and review of the literature.

We report the clinical and pathologic features of an intraoral sebaceous carcinoma and review the literature. The intraoral buccal mucosal tumor from a 50-year-old man was a poorly differentiated carcinoma with sebaceous differentiation and expression of androgen receptor. Fordyce granules and a minor salivary gland with a duct were identified in vicinity to the tumor. We discuss the differential diagnosis and histogenesis. The patient underwent surgery and adjuvant radiation therapy.

Mucoepidermoid carcinoma arising in a background of sialadenoma papilliferum: a case report.

Sialadenoma papilliferum is a rare tumor, primarily of minor salivary gland origin, first described by Abrams and Finck (Cancer 24:1057-63, 1969). It is both an exophytic and endophytic papillary lesion histologically resembling syringocystadenoma papilliferum of sweat gland. The tumor is considered benign although rare recurrent cases have been reported. Three cases of malignant transformation of sialadenoma papilliferum have been described in the literature. We report a high grade mucoepidermoid carcinoma arising in a background of sialadenoma papilliferum, at the base of the tongue, an unusual location for minor salivary gland neoplasms. Eleven months after excision and nodal dissection, there is no evidence of recurrence or metastasis.